Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · February 21, 2020

ASCO GU 2020: Cytoreductive Nephrectomy Linked With Longer Overall Survival in Patients Treated With Immune Checkpoint Inhibition or Targeted Therapy for Metastatic Renal Cell Carcinoma

Cytoreductive nephrectomy may still play a role in selected patients in the immune checkpoint inhibitor era.

PracticeUpdate Editorial Team


Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading